AbbVie Hits Roxane With Patent Suit Over Norvir

Law360, Washington (July 19, 2013, 1:03 PM EDT) -- AbbVie Inc. hit Roxane Laboratories Inc. with an infringement suit in Ohio federal court Thursday, alleging the company's quest to market a generic version of the HIV drug Norvir violates two AbbVie patents.

In its most recent suit against Roxane in its attempts to maintain its position in the HIV treatment market, AbbVie claims the company's revised abbreviated new drug application for generic ritonavir capsules infringes two patents covering AbbVie's branded drug.

The two patents-in-suit were issued in September and March, respectively, and AbbVie has asked...
To view the full article, register now.